Dr Stefan Oschmann Member of the Executive Board and Chief Executive Officer Pharma, Merck KGaA, Darmstadt, Germany, and President of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Inaugural speech-transcript Global health conference “Investing for Healthier Societies: Innovation, Inclusiveness and Sustainability” that the IFPMA is hosting in partnership with Devex (4 November 2014, New...
Read moreDr John C. Lechleiter Chairman, President, and Chief Executive Officer Eli Lilly and Company and IFPMA President Farewell Remarks Global health conference “Investing for Healthier Societies: Innovation, Inclusiveness and Sustainability” that the IFPMA is hosting in partnership with Devex (4 November 2014, New York) (www.ifpmaassembly2014.org). Thank you, Eduardo, and good afternoon, everyone. It’s a pleasure...
Read moreRead more
• PAHO (Pan American Health Organization) Foundation and International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) combine efforts to improve breast and cervical cancer prevention and control. • The partnership aims to improve understanding and practices among primary health care providers and patients for breast cancer screening and early detection as well as increase capacity...
Read moreThis video will be displayed at the opening of the IFPMA Assembly 2014, Investing for healthier societies, a global health conference revolving around inclusiveness, sustainability, and innovation. The event will be live streamed and will take place in New York City on November 4. To learn more about the event, please visit www.ifpmaassembly2014.org
Read moreAs a psychiatrist, I have long worked to address mental diseases such as schizophrenia and depression. Experiencing first-hand the suffering and heavy burden these ailments place on people motivated me early on in my career to better understand the underlying mechanisms of these diseases and to help find new treatment possibilities. This is why I...
Read moreOver 200 years ago, the first vaccine was created to protect against smallpox, an infectious disease that had afflicted humanity for centuries. That discovery opened the door to a golden period of vaccine development that has led to extraordinary improvements in worldwide public health. Today, vaccine development continues to thrive as scientists advance technologies and...
Read moreFaced with the current sudden outbreak of Ebola, the World Health Organization (WHO) consulted experts and researchers engaged in Ebola therapies and vaccines research and development (R&D) in 4-5 September 2014. They decided to expedite the development of two of the most advanced vaccines identified so far: One developed by GlaxoSmithKline in collaboration with the...
Read moreThis IFPMA video interview with Ripley Ballou, who’s in charge of GlaxoSmithKline’s (GSK’s) Ebola vaccine program in Rixensart, Belgium, was recorded soon after Ebola scientists and representatives from companies and regulatory bodies met at the World Health Organization’s (WHO’s) headquarters in Geneva, Switzerland, 4-5 September, to discuss how to speed up clinical development of vaccines,...
Read moreThais want a happy family life and to be healthy, but find it challenging to change behavior. 1 October 2014, Bangkok – The Health Systems Research Institute (HSRI), The Pharmaceutical Research and Manufacturers Association (PReMA), The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Japan Pharmaceutical Manufacturers Association (JPMA) released a joint report...
Read morePushing the boundaries of innovation is at the core of the pharmaceutical industry. However, it’s also the “business model” for many diseases. Microbes, including bacteria and viruses, are constantly evolving to cloak themselves from being affected by antimicrobial medicines. Similarly, aggressive cancers are increasingly becoming unresponsive to first line treatments. In order to stay ahead...
Read more